Shares of PainReform experienced a significant pullback following yesterday's surge, triggered by the company's announcement of a direct offering and concurrent private placement aimed at raising approximately $2.7 million.

The stock opened with a sharp decline of 39%, starting the day at $10.01. Surprisingly, after closing Monday's market at $4.05, the shares soared to an impressive high of $26.41 during midday trading on Tuesday, with no apparent explanation for the sudden increase. When the market closed, the stock settled at $16.50, marking a remarkable fourfold increase from the previous day's closing price.

However, these gains began to unravel during after-hours trading and took a further tumble following PainReform's announcement of a registered direct offering. The clinical-stage specialty pharmaceutical company plans to offer 301,230 shares at a purchase price of $9 per share. Additionally, they will issue warrants to buy the same quantity of shares for $9 each in a private placement.

This offering is slated to conclude on July 14th, and the gross proceeds from both stock sales, amounting to approximately $2.7 million, will be allocated towards various purposes, including funding research and development, conducting clinical trials, and supporting general corporate needs.

BridgeBio Pharma Reports Positive Results for Investigational Drug in Treatment of ATTR-CM

Itaconix Achieves Record-High Revenue for H1 2023

Leave A Reply

Your email address will not be published. Required fields are marked *